Radiofrequency Tumor Ablation — CPB 0492 | AETNA Coverage Update

Aetna modified CPB 0492 governing radiofrequency ablation (RFA) coverage, effective September 26, 2025. Here's what billing teams need to do.

Aetna, a CVS Health company, updated its radiofrequency tumor ablation coverage policy under CPB 0492 in the Aetna clinical policy bulletin system. The revision defines medical necessity criteria across 12 distinct indications — from renal cell carcinoma and malignant lung masses to benign thyroid nodules and osteoid osteoma. The primary affected procedure codes include CPT 20982, 32998, 47370, 47380, 47381, 47382, and 50592, along with HCPCS C1886 for extravascular ablation catheters.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Radiofrequency Tumor Ablation
Policy Code	CPB 0492
Change Type	Modified
Effective Date	September 26, 2025
Impact Level	High
Specialties Affected	Interventional radiology, oncology, urology, thoracic surgery, endocrinology, orthopedic surgery, gastroenterology
Key Action	Audit active RFA cases against the 12 covered indications and confirm ICD-10 diagnosis codes align before billing CPT 20982, 32998, 47370–47382, or 50592

---

Aetna Radiofrequency Ablation Coverage Criteria and Medical Necessity Requirements 2025

The Aetna radiofrequency ablation coverage policy under CPB 0492 is specific. Twelve indications qualify for medical necessity coverage. Each one carries its own clinical criteria. Billing without the right diagnosis and documentation is a direct path to claim denial.

Here are the 12 covered indications as defined in the updated policy:

1. Adrenocortical carcinoma — not amenable to complete surgical resection.

2. Benign thyroid nodules — the member must be an adult with a continuously growing benign nodule greater than 2 cm in diameter, confirmed cytologically benign on fine needle aspiration (FNA) biopsy (CPT 10004–10021), and must be a high-risk surgical candidate.

3. Cancer bone pain — management of refractory bone pain in persons with cancer. CPT 20982 (ablation therapy for bone tumors) applies here.

4. Gastrointestinal stromal tumors (GIST) — treatment of tumors with limited progression. ICD-10 codes C16.0–C18.9 cover metastatic GIST presentations. CPT 43270 and 44369 are relevant for endoscopic ablation in this context.

5. Malignant lung masses — in persons who are not candidates for surgical intervention. Bill CPT 32998 for pulmonary tumor ablation. Confirm the medical record documents surgical ineligibility explicitly.

6. Medullary thyroid carcinoma — treatment of distant metastases only. This is not a blanket thyroid cancer coverage. Distant metastases must be documented.

7. Osteoid osteoma — the member must remain symptomatic despite NSAID treatment, and RFA is used as a less invasive alternative to surgical resection. CPT 20982 applies.

8. Papillary thyroid microcarcinoma — covered without additional sub-criteria in the policy language. Document diagnosis with the appropriate ICD-10 code.

9. Renal cell carcinoma up to 4 cm — coverage applies when the member meets at least one of three criteria: high-risk surgical candidate, renal insufficiency defined as GFR ≤60 ml/min/m², or solitary kidney. CPT 50592 (percutaneous renal tumor ablation) is the primary code here. The 4-cm size threshold is a hard cutoff — anything larger does not meet this indication.

10. Other primary or metastatic malignant neoplasms — removal must be potentially curative, and the member must be unable to tolerate surgical resection. This is a catch-all, but Aetna will look for documentation supporting both the curative intent and the surgical intolerance.

11. Soft tissue sarcoma of the trunk or extremities — for symptomatic persons with disseminated metastases. Not for localized disease.

12. Tumor debulking — as an alternative to surgical (cold knife) resection for primary and metastatic malignant neoplasms. CPT 47370, 47380, 47381, or 47382 may apply depending on approach.

For RFA billing under this coverage policy, prior authorization requirements vary by plan. Check the member's specific Aetna plan for prior auth requirements before scheduling procedures. This is especially true for high-cost codes like CPT 50592 and 47382, where a prior authorization denial after the fact means you carry the reimbursement risk.

---

Aetna Radiofrequency Ablation Exclusions and Non-Covered Indications

The policy defines coverage by inclusion. If an indication is not on the 12-item list, Aetna does not cover it under CPB 0492. That means any RFA procedure billed without a matching covered indication will be denied.

A few areas where billing teams frequently get burned:

Thyroid nodules under 2 cm are not covered, even if the nodule is growing. The policy requires greater than 2 cm diameter plus cytologic confirmation via FNA biopsy (CPT 10004–10021). Submitting without both criteria documented leads to claim denial.

Renal cell carcinoma over 4 cm does not qualify under indication 9. The policy is explicit on the size cutoff. If the tumor exceeds 4 cm, you need a different coverage pathway or a curative-intent argument under indication 10.

Localized soft tissue sarcoma is not covered. The indication requires disseminated metastases. Billing CPT codes for ablation of a single, non-metastatic sarcoma lesion will not align with the policy language.

Osteoid osteoma without prior NSAID trial is not covered. The policy requires documented symptomatic persistence despite NSAIDs before RFA is considered medically necessary. If the chart doesn't show a prior NSAID trial, expect a denial on CPT 20982.

---

Coverage Indications at a Glance

---

Aetna Radiofrequency Ablation Billing Guidelines and Action Items 2025

1. Audit your active RFA cases against the 12 covered indications before billing.
The effective date is September 26, 2025. Any claims submitted on or after that date fall under this revised coverage policy. Pull open orders and pending claims. Match each case to one of the 12 covered indications. If you can't find a match, hold the claim and escalate to your clinical team.

2. Verify ICD-10 diagnosis codes before claim submission.
The policy ties reimbursement to specific diagnoses. For renal cell carcinoma, you need the right C64.x code plus documented tumor size ≤4 cm and one of the three qualifying criteria (surgical risk, GFR ≤60, or solitary kidney). For GIST, pull from C16.0–C18.9. Mismatched diagnosis codes are the fastest way to a claim denial on these procedures.

3. Document the FNA biopsy for thyroid nodule cases.
Benign thyroid nodule coverage requires a cytologically benign FNA biopsy on record. CPT codes 10004–10021 cover FNA procedures — make sure the biopsy is billed and documented before or concurrent with the ablation. A claim for ablation without the supporting FNA documentation is an easy denial.

4. Confirm surgical ineligibility is documented for lung and other malignant neoplasm cases.
For CPT 32998 (malignant lung masses) and the catch-all indication 10, the chart must show why the patient can't have surgery. "Unable to tolerate surgical resection" needs to be in the notes — not implied. A vague physician note won't hold up in a prior authorization review or an appeal.

5. Check prior authorization requirements by plan before scheduling.
The CPB 0492 Aetna system sets the coverage framework, but individual Aetna plan designs control prior authorization requirements. Codes like 50592, 47382, and 32998 carry high reimbursement rates and are frequent targets for PA requirements. Check eligibility and PA status for every case before the procedure date.

6. Update your charge capture templates to reflect the 12-indication structure.
Build the covered indications into your workflow. If your charge capture doesn't prompt for the specific clinical criteria — tumor size for renal cell carcinoma, NSAID trial for osteoid osteoma, surgical candidate status for lung cases — your billing team is guessing. Fix the template before September 26, 2025.

7. Loop in your compliance officer if you're billing the "other malignant neoplasms" catch-all under indication 10.
That indication has two documentation requirements running in parallel: curative intent and surgical intolerance. It's the most subjective indication on the list and the most likely to attract post-payment review. If your team bills CPT 47380 or 47382 under this indication with any frequency, talk to your compliance officer about your documentation standards before the effective date.

---

CPT, HCPCS, and ICD-10 Codes for Radiofrequency Tumor Ablation Under CPB 0492

Covered CPT Codes (When Selection Criteria Are Met)

HCPCS Codes

Code	Type	Description Copy
C1886	HCPCS	Catheter, extravascular tissue ablation, any modality (insertable)

Key ICD-10-CM Diagnosis Codes

The policy includes 349 ICD-10-CM codes in total. The full code list spans malignant neoplasms across multiple organ systems. Pull the complete list from the full CPB 0492 policy document before finalizing your billing guidelines.

---